Literature DB >> 29483302

Molecular and Structural Traits of Insulin Receptor Substrate 1/LC3 Nuclear Structures and Their Role in Autophagy Control and Tumor Cell Survival.

Adam Lassak1,2, Mathew Dean1,2, Dorota Wyczechowska2, Anna Wilk1,2,3, Luis Marrero4, Jimena Trillo-Tinoco1,2, A Hamid Boulares2, Jann N Sarkaria5, Luis Del Valle1,2, Francesca Peruzzi1,2, Augusto Ochoa2, Krzysztof Reiss6,2.   

Abstract

Insulin receptor substrate 1 (IRS-1) is a common cytosolic adaptor molecule involved in signal transduction from insulin and insulin-like growth factor I (IGF-I) receptors. IRS-1 can also be found in the nucleus. We report here a new finding of unique IRS-1 nuclear structures, which we observed initially in glioblastoma biopsy specimens and glioblastoma xenografts. These nuclear structures can be reproduced in vitro by the ectopic expression of IRS-1 cDNA cloned in frame with the nuclear localization signal (NLS-IRS-1). In these structures, IRS-1 localizes at the periphery, while the center harbors a key autophagy protein, LC3. These new nuclear structures are highly dynamic, rapidly exchange IRS-1 molecules with the surrounding nucleoplasm, disassemble during mitosis, and require a growth stimulus for their reassembly and maintenance. In tumor cells engineered to express NLS-IRS-1, the IRS-1/LC3 nuclear structures repress autophagy induced by either amino acid starvation or rapamycin treatment. In this process, IRS-1 nuclear structures sequester LC3 inside the nucleus, possibly preventing its cytosolic translocation and the formation of new autophagosomes. This novel mechanism provides a quick and reversible way of inhibiting autophagy, which could counteract autophagy-induced cancer cell death under severe stress, including anticancer therapies.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  autophagy; cellular distribution; fluorescence recovery after photobleaching; glioblastoma; multiprotein complexes; nuclear suborganelle; phase transition; protein binding; signal transduction

Mesh:

Substances:

Year:  2018        PMID: 29483302      PMCID: PMC5954195          DOI: 10.1128/MCB.00608-17

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  46 in total

1.  Proteomic analysis of interchromatin granule clusters.

Authors:  Noriko Saitoh; Chris S Spahr; Scott D Patterson; Paula Bubulya; Andrew F Neuwald; David L Spector
Journal:  Mol Biol Cell       Date:  2004-05-28       Impact factor: 4.138

2.  Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma.

Authors:  John R Ohlfest; Zachary L Demorest; Yasuhiko Motooka; Isabelita Vengco; Seunguk Oh; Eleanor Chen; Frank A Scappaticci; Rachel J Saplis; Stephen C Ekker; Walter C Low; Andrew B Freese; David A Largaespada
Journal:  Mol Ther       Date:  2005-09-16       Impact factor: 11.454

3.  Molecular mechanisms of fenofibrate-induced metabolic catastrophe and glioblastoma cell death.

Authors:  Anna Wilk; Dorota Wyczechowska; Adriana Zapata; Matthew Dean; Jennifer Mullinax; Luis Marrero; Christopher Parsons; Francesca Peruzzi; Frank Culicchia; Augusto Ochoa; Maja Grabacka; Krzysztof Reiss
Journal:  Mol Cell Biol       Date:  2014-10-20       Impact factor: 4.272

4.  The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage.

Authors:  Dirk Lebrecht; Andrea Geist; Uwe-Peter Ketelsen; Jörg Haberstroh; Bernhard Setzer; Felix Kratz; Ulrich A Walker
Journal:  Int J Cancer       Date:  2007-02-15       Impact factor: 7.396

5.  BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery.

Authors:  Sabrina Facchino; Mohamed Abdouh; Wassim Chatoo; Gilbert Bernier
Journal:  J Neurosci       Date:  2010-07-28       Impact factor: 6.167

6.  Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.

Authors:  Gaspar J Kitange; Brett L Carlson; Mark A Schroeder; Patrick T Grogan; Jeff D Lamont; Paul A Decker; Wenting Wu; C David James; Jann N Sarkaria
Journal:  Neuro Oncol       Date:  2008-10-24       Impact factor: 12.300

7.  Insulin receptor substrate-1 (IRS-1) forms a ribonucleoprotein complex associated with polysomes.

Authors:  Atsufumi Ozoe; Meri Sone; Toshiaki Fukushima; Naoyuki Kataoka; Toshiya Arai; Kazuhiro Chida; Tomoichiro Asano; Fumihiko Hakuno; Shin-Ichiro Takahashi
Journal:  FEBS Lett       Date:  2013-06-13       Impact factor: 4.124

8.  Coexisting Liquid Phases Underlie Nucleolar Subcompartments.

Authors:  Marina Feric; Nilesh Vaidya; Tyler S Harmon; Diana M Mitrea; Lian Zhu; Tiffany M Richardson; Richard W Kriwacki; Rohit V Pappu; Clifford P Brangwynne
Journal:  Cell       Date:  2016-05-19       Impact factor: 41.582

9.  Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme.

Authors:  Amanda Tivnan; Zaitun Zakaria; Caitrín O'Leary; Donat Kögel; Jenny L Pokorny; Jann N Sarkaria; Jochen H M Prehn
Journal:  Front Neurosci       Date:  2015-06-16       Impact factor: 4.677

Review 10.  Standards of care and novel approaches in the management of glioblastoma multiforme.

Authors:  Andreas F Hottinger; Roger Stupp; Krisztian Homicsko
Journal:  Chin J Cancer       Date:  2014-01
View more
  2 in total

1.  Double Labeling Fluorescent Immunocytochemistry.

Authors:  Monika Rak; Krzysztof Reiss
Journal:  Methods Mol Biol       Date:  2022

2.  Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential.

Authors:  J Stalinska; E Zimolag; N A Pianovich; A Zapata; A Lassak; M Rak; M Dean; D Ucar-Bilyeu; D Wyczechowska; F Culicchia; L Marrero; L Del Valle; J Sarkaria; F Peruzzi; B S Jursic; K Reiss
Journal:  Transl Oncol       Date:  2019-05-09       Impact factor: 4.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.